An important finding in our study is the downregulationof β-2AR in cancer patients' lymphocytes.We have demonstrated decreased levels of β-2ARexpression on CD4+IFN-γ+ and CD4+IL-17+ lymphocytesin patients' PBMCs and TILs. The gene discussed is CD4; the disease is cancer.